Discussing Analysts’ Latest Recommendations on VAR Stock
Varian Medical Systems (VAR) is a better-aligned, leaner business with a strong market position after the spin-off of Varex Imaging (VREX) in January 2017.
Varian’s Halcyon Reaches Milestone Achievements
Halcyon is the company’s new treatment platform for cancer patients that visually enhances and simplifies image-guided radiotherapy treatments (or IMRT).
Varian’s Oncology Business Grows in Emerging Markets
Geographic footprint Varian Medical Systems’ (VAR) oncology business reaches around the globe. With a market share of ~60%, It is a leading player in the space. Other major medical device companies in the oncology technology space include Accuray (ARAY), Boston Scientific (BSX), and GE Healthcare, a subsidiary of General Electric (GE). While~50% of the company’s oncology revenue […]
Varian’s Halcyon Treatment System Sees Emerging Market Demand
Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]
Eclipse System Expands Varian’s Market Presence in Australia
On December 12, Varian announced that the Peter MacCallum Cancer Centre in Melbourne had selected its Eclipse treatment planning system for the replacement of its existing platform.
Analyst Recommendations for Varian Medical Systems before 1Q18
Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. It wants to establish itself as the leading cancer management company in the world.
How Has Varian Medical Systems Stock Been Performing Recently?
On December 22, Varian Medical Systems closed the trading day at a price of $110.9. The stock closed 0.18% higher on the day compared to the previous day’s close.
Varian Medical Systems’ Recent Stock Performance
Stock performance Varian Medical Systems (VAR) closed at $96.20 on August 9, 2017. It has a 50-day moving average of $102.30, and a 200-day moving average of $93.20. On August 9, 2017, Varian stock was trading ~27% above its 52-week low of $75.90 on November 9, 2016, and ~10% below its 52-week high of $107.10 on […]
Varian’s Long-Term Growth Strategy: Will It Drive 2018 Guidance?
Varian Medical Systems expects to see fiscal 2018 revenue growth in the range of 2%–4%. Its adjusted diluted EPS (earnings per share) for fiscal 2018 is expected to be $4.20–$4.32.
Here’s What Varian Medical Systems’ Valuation Trend Indicates
Of the nine analysts covering Varian Medical Systems (VAR) stock, three have given it a “strong buy,” three have given it a “hold,” and three have given it a “sell.”
A Look at Accuray’s Therapy Systems
Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types.
Sirtex Medical: Varian Medical Systems’ Latest Acquisition
Sirtex Medical Systems is an Australia-based life sciences company with a presence around the globe. The company is focused on interventional oncology therapies.
Intuitive Surgical’s Da Vinci Procedure Could Boost 2017 Results
According to Intuitive Surgical’s (ISRG) preliminary 4Q17 and 2017 results posted by the company on January 10, 2018, it expects to post da Vinci procedure growth of 17% in 4Q17.
Varian’s Latest Wall Street Recommendations: Mostly ‘Hold’
According to a recent Reuters survey, which included eight investment brokerage firms, six (or 75%) of them have recommended a “hold” for VAR stock.
A Look at Varian Medical Systems’ Long-Term Objectives
Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.
Varian’s Halcyon System Sees Strong Global Growth Momentum
Varian Medical Systems (VAR) received FDA (U.S. Food & Drug Administration) approval in June 2017 for its Halcyon system.
How Varian Medical Systems Is Advancing Cancer Care
Varian Medical Systems (VAR) is the leading radiation oncology technology and solutions company.
Why Most Analysts Recommend a ‘Buy’ for Varian Medical Systems
With its recent spin-off of Varex Imaging (VREX), Varian Medical Systems (VAR) has established itself as a focused cancer management medical technology company.
How Can BSX Improve Its Profitability Going Forward?
In 2Q17, Boston Scientific registered a gross profit margin of 72.8% of its total sales. That compares to 70.7% in 2Q16.
What Drove Varian to Revise Its Revenue Guidance
Company guidance Year-over-year, Varian Medical Systems (VAR) expects its 4Q17 revenue to be flat or fall. According to the company, headwinds from the euro, British pound, and Japanese yen are expected to have an impact of around $10 million, $12 million, and $15 million, respectively. The company’s diluted EPS (earnings per share) are expected to be […]
Why Varian Medical Systems’ Profitability Is Improving
Varian Medical Systems’ profitability In 3Q17, Varian Medical Systems reported a gross margin of approximately 44.5%, representing an 18-basis-point improvement in the quarter. YTD (year-to-date), the margin has improved by around 138 basis points. In 3Q17, the company’s Oncology Systems business witnessed a gross margin improvement of 200 basis points to reach 48.1% of the segment’s total […]
A Look at Varian Medical Systems’ Long-Term Goals
Varian Medical Systems’ long-term goals Varian Medical Systems (VAR) hopes to improve the lives of around 6 million cancer patients each year, which would double what the company has achieved to date. Varian is aiming for 5%–6% annual revenue growth, whereas its current 12-month trailing revenue growth is 3%. Varian aims to achieve a 22% return […]
Analysts’ Recommendations for Varian Medical Systems
With the spin-off of its Imaging Components business, Varian Medical Systems (VAR) is now more aligned with its core capabilities. In this series, we’ll discuss the company’s dynamics after the Varex spin-off.
Varian Medical Systems: Analyzing Its Stock Performance
Varian Medical Systems (VAR) was trading at $102.7 on June 29, 2017. It has a 50-day moving average of $100.4 and a 200-day moving average of $88.8.
Varian Medical Systems Attempts to Improve Its Performance Growth
Varian Medical Systems (VAR) raised its guidance for fiscal 2016 in the view of higher-than-expected 3Q16 results reported on July 27.
How Has Varian Medical Systems Progressed in Radiotherapy?
Varian Medical Systems (VAR) has an innovation-led product pipeline.
What Do Analysts Recommend for Varian Medical Systems?
On June 28, 2016, Goldman Sachs gave Varian Medical Systems a one-year target price of $73, the lowest of all the target prices provided.
What Are the Drivers in the Global Medical Imaging Market?
Varian Medical Systems is a global leader in the imaging components market.
How Varian Is Addressing Existing Gaps in Cancer Treatment
Varian Medical Systems has a large number of initiatives to leverage the expansion opportunities in the oncology market.
Growth Strategies Driving Varian Medical Systems’ Revenue
Varian Medical Systems has ventured into the proton therapy business and has a huge product pipeline in this area. The company generated approximately $300 million through its proton therapy business in 2015.
Varian Medical Systems’ Growth Potential in Radiation Oncology
Varian Medical Systems’ next big technology innovation will be high-definition radiotherapy, which is an intelligent treatment delivery system that aims to achieve 100% radiation exposure for the tumor.
Varian Medical Systems: A Leading Oncology Device Manufacturer
Varian Medical Systems (VAR), headquartered in Palo Alto, California, is a leading radiation oncology treatment device and software manufacturer. It reported revenues of approximately $3.1 billion in 2015.
Where Does Varian Medical Systems Get Most of Its Revenue?
Varian Medical Systems’ Imaging Components segment accounts for approximately 19% of the company’s total revenue. The segment reported a revenue decline of ~10% in 2015.